Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma.
Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma.
复制标题
DOI：
10.1016/j.cca.2013.12.039
复制
发表时间：
2014-03
期刊：
影响因子：
--
通讯作者：
Kengo Fujimura;Hiroyuki Ebinuma;I. Fukamachi;C. Ohwada;T. Kawaguchi;N. Shimizu;M. Takeuchi;E. Sakaida;M. Jiang;C. Nakaseko;H. Bujo
中科院分区：
文献类型：
--
作者：
Kengo Fujimura;Hiroyuki Ebinuma;I. Fukamachi;C. Ohwada;T. Kawaguchi;N. Shimizu;M. Takeuchi;E. Sakaida;M. Jiang;C. Nakaseko;H. Bujo
背景我们报道了可溶性低密度脂蛋白受体11（sLR 11）是滤泡性淋巴瘤（FL）的一个有希望的生物标志物。在这项研究中，我们评估了血清sLR 11水平的波动相比，血清可溶性尿激酶型纤溶酶原激活物受体（suPAR）和可溶性白细胞介素-2受体（sIL-2 R）在非霍奇金淋巴瘤（NHL）的患者。在诊断和缓解的水平进行了评估，在64配对samples.ResultsSerum sLR 11水平显着增加FL，弥漫性大B细胞淋巴瘤（DLBCL），外周T细胞淋巴瘤患者与健康对照组相比。血清sLR 11水平与血清suPAR、sIL-2 R水平呈显著正相关。与诊断时相比，缓解时血清sLR 11水平降低，缓解时下降的斜率约为-1，截距接近对照组。在DLBCL和FL患者中，sLR 11与suPAR和sIL-2 R的受试者工作特征曲线下面积（ROC曲线下面积）相当。结论sLR 11可能是一种新的可溶性受体，可作为NHL的早期诊断指标，并可用于疗效评价。
BackgroundWe reported that the soluble LDL receptor relative with 11 ligand-binding repeats (sLR11) is a promising biomarker for follicular lymphoma (FL). In this study, we evaluated the fluctuations in serum sLR11 levels compared with those of serum soluble urokinase-type plasminogen activator receptor (suPAR) and soluble interleukin-2 receptor (sIL-2R) in patients with non-Hodgkin's lymphoma (NHL).MethodsSerum sLR11, suPAR, and sIL-2R levels were measured using ELISA in 175 NHL patients and 57 healthy controls. The levels at diagnosis and at remission were evaluated in 64 paired samples.ResultsSerum sLR11 levels were significantly increased in FL, diffuse large B-cell lymphoma (DLBCL), and peripheral T-cell lymphoma patients compared with healthy controls. Serum sLR11 levels revealed significant positive correlations with serum suPAR and sIL-2R levels. Serum sLR11 levels at remission were decreased compared with those at diagnosis, and the declines at remission expressed a slope of approximately − 1 with an intercept near that of controls. The receiver operating characteristic–area under the curve of serum sLR11 concentrations was equivalent to that of serum suPAR and sIL-2R concentrations in an early-stage DLBCL and FL.ConclusionssLR11 may be a novel soluble receptor indicative of early-stage NHL, with potential use for evaluating therapeutic efficacy.